Baidu
map

J Endod:血管活性肠肽在尖周组织中的免疫调控作用:来自于人和实验性尖周损伤的关联性和机械学证据

2019-08-20 lishiting MedSci原创

宿主的促炎症免疫反应和其相对抗的抗炎反应及修复反应平衡被认为决定着尖周损伤的预后。血管活性肠肽(VIP)因其显著的免疫调控能力,在此种过程中可能发挥着保护作用。这篇研究的目的是为了从因果的角度评估VIP在人和实验性尖周损伤发展中的潜在作用。

宿主的促炎症免疫反应和其相对抗的抗炎反应及修复反应平衡被认为决定着尖周损伤的预后。血管活性肠肽(VIP)因其显著的免疫调控能力,在此种过程中可能发挥着保护作用。这篇研究的目的是为了从因果的角度评估VIP在人和实验性尖周损伤发展中的潜在作用。

研究通过聚合酶链式反应比较和检测根尖肉芽肿(n = 124)和对照样本(n = 48)中VIP和多种免疫/活性标志物的表达差异。评估实验性根尖损伤(C57Bl/6 wild-type mice)内源性VIP与损伤进展之间的关系以及重组VIP对损伤愈合的作用。采用CCR4KO和IL4KO菌株并通过抑制抗糖皮质激素诱导的TNFR相关蛋白检测Treg和Th2细胞在VIP介导的功效中的作用。

结果显示,VIP在根尖肉芽肿的表达明显高于对照组,并且与免疫调控因子正相关,与促炎症因子和RANkL/骨保护素比例负相关。内源性VIP表达与损伤的免疫调控和骨缺失的减少瞬时相关。小鼠的VIP疗法可以阻止损伤进展,与抗炎和保护反应相关,它能够限制尖周组织促炎症因子、Th1、Th17和破骨相关反应。VIP的保护作用依赖于Treg的迁移和活性,与白细胞介素4无关系。

结论:这些结果表明,VIP在人和实验性尖周损伤处的过表达与损伤静止有明显的关联性,VIP疗法会减弱实验性损伤的进展,这与Treg细胞的免疫抑制反应相关。

原始出处:

de Campos Soriani Azevedo M, Garlet TP, et al. Vasoactive Intestinal Peptide Immunoregulatory Role at the Periapex: Associative and Mechanistic Evidences from Human and Experimental Periapical Lesions. J Endod. 2019 Aug 8. pii: S0099-2399(19)30503-5. doi: 10.1016/j.joen.2019.06.013.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040754, encodeId=7ae62040e54a0, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Apr 11 18:52:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397810, encodeId=087b139e810bd, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545936, encodeId=0d6015459365c, content=<a href='/topic/show?id=9abf4e247a1' target=_blank style='color:#2F92EE;'>#尖周损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47247, encryptionId=9abf4e247a1, topicName=尖周损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021913837714, createdName=12498c24m73暂无昵称, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599294, encodeId=12be159929420, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371612, encodeId=86693e1612ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Aug 21 18:48:30 CST 2019, time=2019-08-21, status=1, ipAttribution=)]
    2020-04-11 lujian
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040754, encodeId=7ae62040e54a0, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Apr 11 18:52:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397810, encodeId=087b139e810bd, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545936, encodeId=0d6015459365c, content=<a href='/topic/show?id=9abf4e247a1' target=_blank style='color:#2F92EE;'>#尖周损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47247, encryptionId=9abf4e247a1, topicName=尖周损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021913837714, createdName=12498c24m73暂无昵称, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599294, encodeId=12be159929420, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371612, encodeId=86693e1612ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Aug 21 18:48:30 CST 2019, time=2019-08-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040754, encodeId=7ae62040e54a0, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Apr 11 18:52:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397810, encodeId=087b139e810bd, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545936, encodeId=0d6015459365c, content=<a href='/topic/show?id=9abf4e247a1' target=_blank style='color:#2F92EE;'>#尖周损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47247, encryptionId=9abf4e247a1, topicName=尖周损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021913837714, createdName=12498c24m73暂无昵称, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599294, encodeId=12be159929420, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371612, encodeId=86693e1612ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Aug 21 18:48:30 CST 2019, time=2019-08-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040754, encodeId=7ae62040e54a0, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Apr 11 18:52:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397810, encodeId=087b139e810bd, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545936, encodeId=0d6015459365c, content=<a href='/topic/show?id=9abf4e247a1' target=_blank style='color:#2F92EE;'>#尖周损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47247, encryptionId=9abf4e247a1, topicName=尖周损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021913837714, createdName=12498c24m73暂无昵称, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599294, encodeId=12be159929420, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371612, encodeId=86693e1612ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Aug 21 18:48:30 CST 2019, time=2019-08-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040754, encodeId=7ae62040e54a0, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Apr 11 18:52:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397810, encodeId=087b139e810bd, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545936, encodeId=0d6015459365c, content=<a href='/topic/show?id=9abf4e247a1' target=_blank style='color:#2F92EE;'>#尖周损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47247, encryptionId=9abf4e247a1, topicName=尖周损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021913837714, createdName=12498c24m73暂无昵称, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599294, encodeId=12be159929420, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Thu Aug 22 12:52:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371612, encodeId=86693e1612ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Aug 21 18:48:30 CST 2019, time=2019-08-21, status=1, ipAttribution=)]
    2019-08-21 phoebeyan520

    学习了

    0

相关资讯

“特需”不衰是因为“需”字在作怪?

特需”医疗是与普通医疗相区别的,无论在医疗技术、医疗服务还是医疗价格上都上了一个层次。上世纪末,“特需”是身份的体现,现在这种身份识别已经取消。不过,有些人认为“特需”医疗挤占了公共医疗资源,应该将其取缔,一些医院也做了许多尝试。但实际情况是,“特需”不但取不了,还在逐年增加,这究竟是为什么? 对于特需医疗,上海市最先“开刀”。2011年5月,《上海市医疗机构设置规划2011~2015》提出

J Periodontol:唾液神经肽、应激与牙周炎

目前心理压力作为牙周炎风险因素还没有确切的科学证据,主要依据问卷或生物标记研究。本项研究的目的是调查脑源性神经营养因子,P物质,血管活性肠肽(VIP),神经肽Y(NPY),降钙素基因相关肽和肾上腺髓质素以及唾液和血清中的皮质醇,以及牙周健康和疾病与压力的不同方面以及与临床参数可能的关联相结合。

Baidu
map
Baidu
map
Baidu
map